Table 1 General characteristics of included studies.

From: A systematic review and quality assessment of economic evaluations of kidney replacement therapies in end-stage kidney disease

 

Study

Country

Region

Country income level

Economic evaluation type

Approach

Perspective

Time horizon (years)

Discount rate (costs and outcomes)

1.

Yang et al. [2021] 10

China

WPR

Upper-MIC

CUA

Pairwise & Scenario-based

Third-Party Payer

5, 10, 15

5%

2.

Bayani et al. [2021] 18

Philippines

SEAR

Lower-MIC

CUA

Scenario-based

Public Healthcare & Societal

Lifetime

3%

3.

Moradpour et al. [2020] 11

Iran

EMR

Lower-MIC

CUA

Pairwise

Societal

Lifetime

6%

4.

Rosselli et al. [2015] 47

Columbia

AMR

Upper-MIC

CUA&CEA

Pairwise

Third-Party Payer

1, 2, 3, 5

3%

5.

Jensen et al. [2014] 43

Denmark

EUR

HIC

CUA

Pairwise

Public Healthcare

6

3.5%

6.

Villa et al. [2012] 19

Spain

EUR

HIC

CUA

Scenario-based

Societal

5, 10, 15

3.5%

7.

Shimizu et al. [2012] 50

Japan

WPR

HIC

CUA

Scenario-based

Public Healthcare

15

3%

8.

Haller et al. [2011] 46

Austria

EUR

HIC

CUA&CEA

Scenario-based

Public Healthcare

10

3%

9.

Howard et al. [2009] 20

Australia

WPR

HIC

CUA&CEA

Scenario-based

Public Healthcare

5

5%

10.

Kontodimopoulos et al. [2008] 44

Greece

EUR

HIC

CUA

Pairwise

Public Healthcare

Lifetime

5%

11.

de Wit et al. [1998] 45

Netherlands

EUR

HIC

CUA&CEA

Scenario-based

Societal

5

5%

12.

Arredondo et al. [1998] 48

Mexico

AMR

Upper-MIC

CUA&CEA

Pairwise

Public Healthcare

5

5%

13.

Sesso et al. [1990] 49

Brazil

AMR

Upper-MIC

CEA

Pairwise

Third-Party Payer

2

No discounting

  1. AMR, American Region; CEA, Cost-Effectiveness Analysis; CKD, Chronic Kidney Disease; CUA, Cost-Utility Analysis; EMR, Eastern Mediterranean Region; ESKD, End-stage kidney disease, EUR, European Region; HIC, High Income Country; MIC, Middle Income Country; SEAR, South-East Asia Region; UMIC, Upper-Middle Income Country; WPR, West Pacific Region.